At Uromigos Live 2024, a panel moderated by Tom Powles focused on IO rechallenge in renal cell carcinoma, featuring discussion on new trial data and more. The panel included Brian Rini, along with Tian Zhang, MD, UT Southwestern Medical Center; Toni Choueiri, MD, Dana-Farber Cancer Center; and David McDermott, MD, Beth Israel Deaconess Medical Center.
Part two of the panel features a discussion on the timing and rationale behind conducting trials for re-challenging patients with PD-1 inhibitors after prior adjuvant pembrolizumab therapy. The panel explores key questions regarding the appropriate gap between treatments and the potential scientific value of conducting such studies. The conversation also touches on audience feedback through polls, debating whether a new PD-1 inhibitor trial is necessary and what the best time frame for such studies might be.
Uromigos Live 2024 RCC IO Rechallenge Part 2: Do We Need a Post-Adjuvant Pembrolizumab Study?
By Thomas Powles, MBBS, MRCP, MD, Brian Rini, MD, FASCO, Tian Zhang, MD, Toni Choueiri, MD, David F. McDermott, MD - Last Updated: October 29, 2024Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.